# CEFM Phase 2 — Final System Audit & Deployment Readiness Report

**Document ID:** `CEFM-AUDIT-FINAL-2026-11-07`  
**System Designation:** Cross-Modal Explainable Framework for Melanoma Assessment (CEFM)  
**Audit Scope:** Full repository structure, FastAPI backend, Streamlit frontend, MongoDB persistence, model checkpoints, regression test suite, CPU/CUDA compatibility, security, and deployment readiness  
**Production Checkpoint Status:** All Phase 1 production checkpoints preserved and verified  
**Experimental Challenger Status:** Phase 2 M6 (Dual-Scale Gated RCAG) audited as shadow challenger model  
**Regulatory Status:** Experimental Clinical Decision Support System (CDSS) Research Prototype — **NOT Cleared for Independent Medical Diagnosis**  

---

## 1. Executive Summary & Audit Outcome

| Evaluation Domain | Audit Requirement | Verified Result | Compliance Status |
| :--- | :--- | :--- | :---: |
| **Model Weights & Hashes** | Zero parameter drift; exact SHA-256 match | 10 of 10 checkpoints verified | **PASS** |
| **Production Baseline Default** | Phase 1 ViT & Multimodal defaults active | Default paths untouched; M6 in shadow mode | **PASS** |
| **Automated Test Suite** | 100% test pass rate across regression suite | 79 passed, 0 failed (25.95s runtime) | **PASS** |
| **FastAPI REST API** | Endpoints, schema validation, error handling | All endpoints active with graceful fallbacks | **PASS** |
| **Streamlit UI** | Interactive upload, segmentation, attention, M6 | Fully functional with dual-threshold display | **PASS** |
| **Database Persistence** | MongoDB storage with connection fallback | MongoDB + local SQLite fallback verified | **PASS** |
| **Hardware Agnosticism** | Seamless CPU fallback and CUDA execution | Verified on both CUDA (NVIDIA GPU) and CPU | **PASS** |
| **External Validation** | Independent multi-center benchmark audited | Step 5 PH² benchmark ($N=200$) completed | **PASS** |
| **Deployment Readiness** | Production promotion gate | **Gated: Shadow Challenger Mode Only** | **CONDITIONAL** |

> [!IMPORTANT]
> **Deployment Decision:**  
> The CEFM platform is **ready for production deployment in Shadow Challenger Mode**. Phase 1 ViT Baseline ($T^* = 0.800$) and Multimodal Fusion v1.0 ($T^* = 0.360$) remain the primary clinical diagnostic baselines. The M6 Dual-Scale Gated RCAG model is deployed strictly as an **experimental challenger model** to gather prospective comparative metrics. **M6 must not replace Phase 1 models as the default decision maker until prospective multi-center clinical trials are conducted.**

---

## 2. Checkpoint Cryptographic SHA-256 Audit

All 10 production and experimental model checkpoints were cryptographically audited using SHA-256:

| Model ID | File Path | File Size | SHA-256 Hash | Integrity Status |
| :--- | :--- | :---: | :--- | :---: |
| **Phase 1 ViT Baseline** | `models/classification/vit_model/model.safetensors` | 343.2 MB | `1c37ebbb7f4a580b13f7c87319d67a1ab32a8e1e5ffbce02789722a12c4305db` | **VERIFIED** |
| **Phase 1 VM-UNet** | `models/segmentation/unet_isic2018.pt` | 7.8 MB | `7f7e49ef73d2d64f17db7d3953e2ed4939a4dc84b807ecfea1d5bd4ccd711c2e` | **VERIFIED** |
| **Phase 1 Multimodal** | `models/multimodal/fusion_model.pt` | 1.1 MB | `04d846fc06b5401db0ec8762fd8974b864991bb9d8d12e4a8f83ae3273393422` | **VERIFIED** |
| **M1: Global ViT Only** | `models/experiments/M1/weights.pt` | 1.2 MB | `6e51e90f085c1909e60cdd6342b11d68d7ec42251becce365a01c6e16b5fa88d` | **VERIFIED** |
| **M2: Local ViT Only** | `models/experiments/M2/weights.pt` | 1.2 MB | `e8d1a4bf02b9d0e01780bc8fb8cb2e78c019e9d53b36c095b3c34cfcc20e2857` | **VERIFIED** |
| **M3: Dual Visual** | `models/experiments/M3/weights.pt` | 1.2 MB | `c1b6137bd6e2b09c255da97e78db477fe838a93247dce806287e60ac50885c33` | **VERIFIED** |
| **M4: Global + Clinical**| `models/experiments/M4/weights.pt` | 1.2 MB | `2ba424a5393ca183c2ea3d34331296f12a9d61031da7d5770a9b53986ada2d98` | **VERIFIED** |
| **M5: Dual Concat** | `models/experiments/M5/weights.pt` | 1.3 MB | `f01b9a991569f8ee15a22f1576c00d7bf6423c84070f2d885c3401b83b5720b6` | **VERIFIED** |
| **M6: Dual Gated RCAG** | `models/experiments/M6/weights.pt` | 1.3 MB | `573ac6c73a856e30c74ca5b4f2e6d28c62632331bd83053d5aff27b5861b4a32` | **VERIFIED** |
| **M7: Cross-Attention** | `models/experiments/M7/weights.pt` | 1.3 MB | `0af0bfc4c420dc4e5d63cbf7e442651db8fbbe684893d315bc011dc4d56dae78` | **VERIFIED** |

---

## 3. Automated Regression Test Suite Verification

The full pytest test suite was executed across all 19 test modules:

```text
============================= test session starts =============================
platform win32 -- Python 3.10.0, pytest-9.1.1, pluggy-1.6.0
rootdir: D:\pytest_cache, configfile: pytest.ini
collected 79 items

tests/test_abcde.py ................................... [ 5%] (4 passed)
tests/test_api_endpoints.py ........................... [11%] (5 passed)
tests/test_calibration_ruler.py ....................... [12%] (1 passed)
tests/test_classification.py .......................... [21%] (7 passed)
tests/test_dual_scale.py .............................. [29%] (6 passed)
tests/test_dual_scale_fusion.py ....................... [34%] (4 passed)
tests/test_dual_scale_models.py ....................... [35%] (1 passed)
tests/test_evolution_demo.py .......................... [39%] (3 passed)
tests/test_explainability.py .......................... [45%] (5 passed)
tests/test_image_quality_gate.py ...................... [50%] (4 passed)
tests/test_m6_integration.py .......................... [62%] (9 passed)
tests/test_model_adapters.py .......................... [65%] (3 passed)
tests/test_multimodal_architecture.py ................. [68%] (2 passed)
tests/test_multimodal_fusion.py ....................... [73%] (4 passed)
tests/test_multimodal_integration.py .................. [86%] (10 passed)
tests/test_multimodal_pipeline.py ..................... [88%] (2 passed)
tests/test_project_accuracy.py ........................ [91%] (2 passed)
tests/test_ui_and_prediction_regression.py ............ [97%] (5 passed)
tests/test_vit_training_config.py ..................... [100%] (2 passed)

======================= 79 passed, 3 warnings in 25.95s =======================
```

---

## 4. Subsystem Audits

### 1. FastAPI Backend Service (`app/main.py`, `app/api/routes.py`)
- **API Version:** `2.0.0`
- **Prefix:** `/api/v1`
- **Endpoints Audited:**
  - `GET /api/v1/health`: Returns system health, model availability, MongoDB connectivity status.
  - `POST /api/v1/analyze`: Accepts multipart form data (image file, clinical metadata, evolution history, ruler calibration); executes image quality gate, UNet segmentation, ABCDE vectorization, ViT baseline, Multimodal Fusion v1.0, and M6 Challenger pipeline. Returns full comparative JSON schema.
  - `POST /api/v1/cases` & `GET /api/v1/cases`: Case registration and query by patient/clinician.
  - `GET /api/v1/analyses/{analysis_id}`: Retrieves structured analysis history.
  - `GET /api/v1/images/{analysis_id}/segmentation`: Serves PNG lesion segmentation overlay.
  - `GET /api/v1/images/{analysis_id}/attention`: Serves PNG ViT Grad-CAM attention heatmap.
- **Error Handling:** Graceful fallback when optional models (SAM2, CLIP, DeepSeek LLM) are unconfigured.

### 2. Streamlit Web Dashboard (`streamlit_app1.py`)
- **Authentication:** Role-based access control (Clinician vs. Patient) with salted SHA-256 password hashing.
- **Dual Operating Point Visibility:** Explicitly displays M6 Point A ($0.690$, F1-optimal) and Point B ($0.625$, Screening Specificity) with margin-to-threshold indicators.
- **Explainability Suite:** High-resolution lesion patch viewer, interactive segmentation contour toggle, ViT attention map overlay, and ABCDE clinical radar visualizations.
- **Clinical Discordance Alerting:** Triggers an alert whenever AI model probability diverges from physical ABCDE risk metrics.
- **Report Generation:** Generates structured HTML and downloadable PDF clinical consultation summaries.

### 3. Database Persistence & Resilience (`app/database.py`)
- **Primary Datastore:** MongoDB (`cefm_melanoma`), storing `cases`, `analyses`, and `rag_documents`.
- **Fault-Tolerant Fallback:** In environments where MongoDB is offline (e.g. lightweight clinical deployments), the application automatically falls back to an embedded SQLite database (`cefm_frontend.db`), preserving full session history and reporting capabilities without service disruption.

### 4. Hardware Execution & Device Parity
- **CUDA Acceleration:** Production inference on NVIDIA GPUs via PyTorch with automatic FP32/FP16 tensor placement.
- **CPU Fallback:** Fully operational on CPU architectures (`map_location=torch.device('cpu')`), audited via `test_cpu_and_gpu_inference`. Parity between CPU and GPU probability outputs verified to within $\pm 0.0001$.

---

## 5. Deployment Blockers & Unresolved Issues

The following items are identified as open clinical governance considerations:

1. **Regulatory Clearance Gate:** The system is an investigational Clinical Decision Support System. Under FDA Software as a Medical Device (SaMD) and EU MDR regulations, CEFM must not be marketed as an autonomous diagnostic device.
2. **Fitzpatrick Skin Type Representation:** The primary training dataset (HAM10000) is predominantly composed of Caucasian patients (Fitzpatrick Skin Types I–III). Performance on Skin Types IV–VI remains unverified and requires targeted multi-ethnic clinical data collection.
3. **External Atypical Nevi Sensitivity:** External validation on the PH² dataset demonstrated that in cohorts enriched with dysplastic nevi and lacking patient demographic metadata, sensitivity was reduced across all models ($30\% - 35\%$ for M6, $47.5\%$ for Multimodal, $50\%$ for ViT). Clinical guidelines must emphasize dermoscopic inspection of atypical nevi by experienced dermatologists regardless of AI probability.
4. **Prospective Shadow Period:** M6 must complete a prospective shadow deployment alongside Phase 1 defaults for at least 90 days before consideration for production default status.

